Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in pat… Read more
Market Cap & Net Worth: Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc (NASDAQ:TCRX) has a market capitalization of $57.19 Million ($57.19 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21130 globally and #7607 in its home market, demonstrating a -12.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tscan Therapeutics Inc's stock price $1.09 by its total outstanding shares 52471405 (52.47 Million).
Tscan Therapeutics Inc Market Cap History: 2021 to 2026
Tscan Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $236.12 Million to $57.19 Million (-38.43% CAGR).
Index Memberships
Tscan Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #575 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1900 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.00% | #242 of 263 |
Weight: Tscan Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tscan Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tscan Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
56.65x
Tscan Therapeutics Inc's market cap is 56.65 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $236.12 Million | $10.14 Million | -$48.62 Million | 23.28x | N/A |
| 2022 | $81.33 Million | $13.54 Million | -$66.22 Million | 6.01x | N/A |
| 2023 | $305.91 Million | $21.05 Million | -$89.22 Million | 14.53x | N/A |
| 2024 | $159.51 Million | $2.82 Million | -$127.50 Million | 56.65x | N/A |
Competitor Companies of TCRX by Market Capitalization
Companies near Tscan Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Tscan Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Tscan Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Tscan Therapeutics Inc's market cap moved from $236.12 Million to $ 57.19 Million, with a yearly change of -38.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.19 Million | +9.00% |
| 2025 | $52.47 Million | -67.11% |
| 2024 | $159.51 Million | -47.86% |
| 2023 | $305.91 Million | +276.13% |
| 2022 | $81.33 Million | -65.56% |
| 2021 | $236.12 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tscan Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.19 Million USD |
| MoneyControl | $57.19 Million USD |
| MarketWatch | $57.19 Million USD |
| marketcap.company | $57.19 Million USD |
| Reuters | $57.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.